The Role of Immune Semaphorins in NAFLD

CompletedOBSERVATIONAL
Enrollment

160

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

March 1, 2022

Conditions
Non-Alcoholic Fatty Liver DiseaseImmune ResponseBiomarkersLiver FibrosisNon Alcoholic Steatohepatitis
Interventions
DIAGNOSTIC_TEST

Evaluation of the degree of fibrosis and steatosis

The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.

DIAGNOSTIC_TEST

Screening for the components of metabolic syndrome

"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."

DIAGNOSTIC_TEST

Measurement of serum semaphorin concentrations

Semaphorin concentration will be measured in patient sera by ELISA.

DIAGNOSTIC_TEST

Identification of semaphorin gene polymorphisms

Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.

Trial Locations (1)

10000

University Hospital for Infectious Diseases Zagreb, Zagreb

All Listed Sponsors
collaborator

Croatian Science Foundation

OTHER_GOV

lead

University Hospital for Infectious Diseases, Croatia

OTHER

NCT04573543 - The Role of Immune Semaphorins in NAFLD | Biotech Hunter | Biotech Hunter